Department of Nephrology, Kantonsspital Liestal, Switzerland.
Swiss Med Wkly. 2012 May 2;142:w13578. doi: 10.4414/smw.2012.13578. eCollection 2012.
We assessed the long-term follow up of all the patients with fibrillary glomerulonephritis diagnosed since 1992 at our centre of reference for renal pathology in Basel.
We performed a retrospective surveillance study with mail questionnaire based follow-up of all patients with the diagnosis of fibrillary glomerulonephritis found in the database of the department of renal pathology in Basel from 1992 to 2007. The outcome was assessed in terms of endstage renal disease (ESRD), death, reduction of proteinuria and improvement of estimated glomerular filtration rate (eGFR).
We obtained sufficient follow up data from 16 out of 20 identified patients. The mean follow up time was 35 months (1-115.1). Six patients died (37.5%), three without having ESRD. Six patients (37.5%) reached ESRD, five of them went on hemodialysis. Thirteen patients (81.3%) received an immunosuppressive therapy with steroids, five of them in combination with cyclophosphamide. The group without immunosuppressive therapy was too small to compare the two groups. In relation to the histological pattern membranous glomerulonephritis (MGN) had a better outcome as compared to the other histological patterns.
FGN is a heterogeneous disease associated with significant risk of ESRD and mortality. The histological type of the glomerulonephritis may influence the course of the disease.
我们评估了自 1992 年以来在我们巴塞尔肾脏病理参考中心诊断的所有纤维状肾小球肾炎患者的长期随访情况。
我们对巴塞尔肾脏病理系数据库中 1992 年至 2007 年诊断为纤维状肾小球肾炎的所有患者进行了回顾性监测研究，并通过邮件问卷进行了随访。根据终末期肾病（ESRD）、死亡、蛋白尿减少和估算肾小球滤过率（eGFR）改善来评估结果。
我们从 20 名确诊患者中获得了足够的随访数据。平均随访时间为 35 个月（1-115.1）。6 名患者死亡（37.5%），其中 3 名未发生 ESRD。6 名患者（37.5%）达到 ESRD，其中 5 名接受血液透析。13 名患者（81.3%）接受了类固醇免疫抑制治疗，其中 5 名联合使用环磷酰胺。由于未接受免疫抑制治疗的患者数量太少，无法对两组进行比较。与其他组织学类型相比，膜性肾小球肾炎（MGN）的组织学类型具有更好的预后。
FGN 是一种异质性疾病，与 ESRD 和死亡率的高风险相关。肾小球肾炎的组织学类型可能会影响疾病的进程。
